Andolast and other Novel Emerging Therapies for Erectile Dysfunction 2021

Post any data on Treatments and experimentation.
User avatar
anacleta
Posts: 695
Joined: Fri Jan 23, 2015 5:47 am
Contact:

Andolast and other Novel Emerging Therapies for Erectile Dysfunction 2021

Unread post by anacleta »

Following the NS1619 investigations, a more selective
maxi-K channel, NS11021, has been developed. NS11021
increases potassium currents in vascular smooth
muscle, reduces vascular tension of penile arteries and
CC strips, and induces erection in anesthetized rats.
The efficacy of effect was similar to that of sildenafil
[70]. A similar study conducted in human penile small
arteries and NS11021 evoked pronounced relaxations
that led to erectile response [71]. Currently, andolast is the only candidate drug targeting maxi-K channels for
treatment of ED in clinical development. Well-designed
clinical studies are needed to evaluate the treatment
outcomes of andolast in ED patients.

Novel Emerging Therapies for Erectile Dysfunction

https://wjmh.org/Synapse/Data/PDFData/2 ... 38-e15.pdf
User avatar
kpavel
Posts: 325
Joined: Thu Aug 15, 2019 7:50 am
Contact:

Re: Andolast and other Novel Emerging Therapies for Erectile Dysfunction 2021

Unread post by kpavel »

Hypercontractility and impaired sildenafil relaxations in the BKCa channel deletion model of erectile dysfunction
https://pubmed.ncbi.nlm.nih.gov/18480246/
Erectile dysfunction (ED) can be elicited by a variety of pathogenic factors, particularly impaired formation of and responsiveness to nitric oxide (NO) and the downstream effectors soluble guanylate cyclase (sGC) and cGMP-dependent protein kinase I (PKGI). One important target of PKGI in smooth muscle is the large-conductance, Ca2+ -activated potassium (BKCa) channel. In our previous report (42), we demonstrated that deletion of the BKCa channel in mice induced force oscillations and led to reduced nerve-evoked relaxations and ED. In the current study, we used this ED model to explore the role of the BKCa channel in the NO/sGC/PKGI pathway. Electrical field stimulation (EFS)-induced contractions of corpus cavernosum smooth muscle strips were significantly enhanced in the absence of BKCa channel function. In strips precontracted with phenylephrine, EFS-induced relaxations were converted to contractions by inhibition of sGC, and this was further enhanced by loss of BK channel function. Sildenafil-induced relaxations were decreased to a similar extent by inhibition of sGC or BKCa channels. At concentrations >1 microM, sildenafil caused relaxations independent of inhibition of sGC or BKCa channels. Sildenafil did not affect the enhanced force oscillations that were induced by the loss of BKCa channel function. Yet, these oscillations could be completely eliminated by blocking L-type voltage-dependent Ca2+ channels (VDCCs). These results suggest that therapeutically relevant concentrations of sildenafil act through cGMP and BKCa channels, and loss of BKCa channel function leads to hypercontractility, which depends on VDCCs and cannot be modified by the cGMP pathway.

Same for male & female ED
https://pubmed.ncbi.nlm.nih.gov/15333581/
https://pubmed.ncbi.nlm.nih.gov/12378824/

Maxi-K and BKCa are synonyms.
Post Reply

Who is online

Users browsing this forum: No registered users and 10 guests